Study to Evaluate the Effect of Nicotinamide Riboside on Immunity
Study Details
Study Description
Brief Summary
Background:
The immune system controls how the body responds to infection or injury. Researchers want to see what effect a dietary supplement called nicotinamide riboside (NR) has on the immune system. A study showed that fasting has a good effect on immune cell health in healthy people. And when immune cells were exposed to NR they had a similar positive response as with fasting. Researchers want to see if healthy people have the same effects from NR and fasting, and if those effects last.
Objectives:
To see if taking nicotinamide riboside will have the same healthy immune system effects as fasting. To see if these good effects continue even after eating again.
Eligibility:
Healthy volunteers ages 18 - 39 years
Design:
Participants will be screened with medical history, physical exam, and blood tests. Women will have a urine pregnancy test.
Participants will take 4 pills of either NR or a placebo once a day for 1 week.
On day 6, they will not eat or drink anything.
On day 7, they will have a study visit to give a blood sample before and after eating a meal at the clinic.
They will also give a urine sample.
Participants will stop taking the pills for 1 2 weeks.
Participants will take either NR or a placebo once a day for 1 week.
They will repeat day 6 and day 7 of the first week.
Participants will get NR once and placebo once, but will not know which they are taking.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Intermittent caloric restriction or fasting has numerous health effects including the reduction in numerous cardiovascular disease risk factors. The cellular programs activated by caloric restriction are similarly turned on in preclinical studies in response to a 24-hour fast. We have found that a beneficial effect of 24-hour fasting is that it blunts the activation of a component of the immune system, termed the Nod-like receptor family protein 3 (NLRP3) Inflammasome. This inflammasome, as a mediator of sterile inflammation, is associated with the development of diabetes and atherosclerosis. At the same time, we found that refeeding after the 24-hour fast significantly increased NLRP3 protein levels, IL-1Beta, and TNF signaling, and that fasting blunted the NLRP3 inflammasome response, in association with the activation of a fasting sensing protein called SIRT3. Interestingly, a recently discovered naturally occurring form of vitamin B3, called nicotinamide riboside (NR), has been found to activate SIRT3. We found that NR reproduces the NLRP3 inflammasome blunting effect of fasting when administered to primary human monocytes/macrophages in culture. Putting this together, it would be interesting to evaluate whether the administration of NR to human subjects would replicate the fasting blunting effect on the NLRP3 inflammasome. Interestingly, at the same time, it has recently been found, in a preclinical study, that the NLRP3 protein can orchestrate differentiation of naive T- cells into Th2 cells. We therefore propose to more broadly examine the effects of NR administration on myeloid and lymphoid cell biology in healthy volunteers.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Arm 1 Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment. |
Dietary Supplement: Nicotinamide riboside (NR)
NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
Drug: Placebo
Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
|
| Experimental: Arm 2 Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment. |
Dietary Supplement: Nicotinamide riboside (NR)
NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
Drug: Placebo
Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
|
Outcome Measures
Primary Outcome Measures
- Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast [4 weeks]
The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days.
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
As this is a pilot study, the age-range and BMI range of subjects will be restricted to potentially reduce metabolic variables associated with a wide age- and BMI-range.
-
Males and females between the ages of 18 and 39
-
BMI between 18.5 and 29.9
-
Agrees to comply with study procedures and maintain current level of physical activity and dietary intake throughout the study.
-
Female subjects of child-bearing ability willing to commit to reliable contraception while participating in the study.
EXCLUSION CRITERIA:
-
Subjects with an acute or chronic illness as per history, on laboratory analysis or requiring medications to manage disease.
-
Subjects taking vitamins or supplements or any medications, except oral contraceptives, within 4 weeks of participation into this study.
-
BMI <18.5 or >29.9.
-
Female subjects who are pregnant or lactating.
-
Subjects who have donated blood or participated in another clinical trial involving blood draws in the last 8 weeks.
-
Subjects who use nicotine products including chewing tobacco, vaporizer, gum, cigarette or patch form within three months.
-
Any other medical condition that, in the opinion of the Principal Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institutes of Health Clinical Center | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Investigators
- Principal Investigator: Michael N Sack, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Study Documents (Full-Text)
More Information
Additional Information:
Publications
- Brown KD, Maqsood S, Huang JY, Pan Y, Harkcom W, Li W, Sauve A, Verdin E, Jaffrey SR. Activation of SIRT3 by the NAD⁺ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 2014 Dec 2;20(6):1059-68. doi: 10.1016/j.cmet.2014.11.003.
- Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012 Jun 6;15(6):838-47. doi: 10.1016/j.cmet.2012.04.022.
- Traba J, Kwarteng-Siaw M, Okoli TC, Li J, Huffstutler RD, Bray A, Waclawiw MA, Han K, Pelletier M, Sauve AA, Siegel RM, Sack MN. Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects. J Clin Invest. 2015 Nov 3;125(12):4592-600. doi: 10.1172/JCI83260.
- 160129
- 16-H-0129
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Nicotinamide Riboside, Then Placebo | Placebo, Then Nicotinamide Riboside |
|---|---|---|
| Arm/Group Description | These subjects were first administered Nicotinamide riboside at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo for one additional week. | These subjects were first administered Placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to Nicotinamide riboside at 1000mg/day for one week. |
| Period Title: First Intervention | ||
| STARTED | 19 | 19 |
| COMPLETED | 18 | 19 |
| NOT COMPLETED | 1 | 0 |
| Period Title: First Intervention | ||
| STARTED | 18 | 19 |
| COMPLETED | 18 | 18 |
| NOT COMPLETED | 0 | 1 |
Baseline Characteristics
| Arm/Group Title | All Subjects |
|---|---|
| Arm/Group Description | Baseline data for all subjects on the study. |
| Overall Participants | 38 |
| Age (Count of Participants) | |
| <=18 years |
0
0%
|
| Between 18 and 65 years |
38
100%
|
| >=65 years |
0
0%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
24
63.2%
|
| Male |
14
36.8%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
0
0%
|
| Not Hispanic or Latino |
34
89.5%
|
| Unknown or Not Reported |
4
10.5%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
11
28.9%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
8
21.1%
|
| White |
15
39.5%
|
| More than one race |
1
2.6%
|
| Unknown or Not Reported |
3
7.9%
|
Outcome Measures
| Title | Mean IL-1 Beta Release From Peripheral Blood Mononuclear Cells During Refeeding After 24 Hour Fast |
|---|---|
| Description | The IL- 1beta secretion is measured in response to fasting, refeeding and administration of Nicotinamide Riboside (or placebo). Nicotinamide riboside acts as a fasting mimetic, and is supposed to maintain the reduction of IL-1 beta secretion (indicating NLRP3 inflammasome activation) induced by fasting. 1000 mg of Nicotinamide riboside on a daily basis is given to the subjects for a period of 7-10 days. |
| Time Frame | 4 weeks |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Nicotinamide Riboside | Placebo |
|---|---|---|
| Arm/Group Description | In this crossover design the study subjects from both arms that had received NR at 1000mg/days/7days, were combined to analyze the effect of NR on IL-1beta secretion in response to refeeding. | In this crossover design the study subjects from both arms that had received placebo for days, were combined to analyze the effect of NR on IL-1beta secretion in response to refeeding. |
| Measure Participants | 36 | 36 |
| Mean (Standard Deviation) [mg/dL] |
582
(612)
|
794
(941)
|
Adverse Events
| Time Frame | 4 weeks | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Nicotinamide Riboside | Placebo | ||
| Arm/Group Description | These subjects were administered Nicotinamide riboside | These subjects were administered Placebo | ||
All Cause Mortality |
||||
| Nicotinamide Riboside | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/38 (0%) | 0/38 (0%) | ||
Serious Adverse Events |
||||
| Nicotinamide Riboside | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/38 (0%) | 0/38 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Nicotinamide Riboside | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 3/38 (7.9%) | 2/38 (5.3%) | ||
| General disorders | ||||
| Headache | 1/38 (2.6%) | 1/38 (2.6%) | ||
| Respiratory, thoracic and mediastinal disorders | ||||
| Upper respiratory tract infection | 2/38 (5.3%) | 1/38 (2.6%) | ||
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Dr. Michael N. Sack |
|---|---|
| Organization | NHLBI |
| Phone | 301-402-9259 |
| sackm@nih.gov |
- 160129
- 16-H-0129